Peptides for Disease Research

We’re rapidly producing custom peptides and peptide libraries for the major proteins of SARS-COV-2. With high quality products available fast for researchers combating Covid19, come and see Mimotopes for all of your peptide needs.

Custom Peptide Libraries

The advantage of our proprietary parallel synthesis technology is that Mimotopes can synthesise hundreds of peptides simultaneously, and thus greatly reduce the price and time to delivery.

High quality Peptide Libraries affordable prices

30 Years Experience

Mimotopes is the founder of peptide library technology. We have only continued to grow and learn over the decades – now our expertise is unrivaled.

We work tirelessly to stay ahead of the game to ensure, as always, that we supply the best possible products, including SARS-CoV-2 peptides.

Efficient & Economical Screening Solutions

PepsetTM PeptideLibraries have dozens of potential applications. With applications in covid19 vaccine and drug development, disease screening, and epitope mapping, a peptide library can be exclusively designed to your specifications, for your research. 

  • Discover crucial residues with an Alanine Scan Library
  • Map epitopes with an Overlapping Library
  • Narrow down the shortest active sequences with a Truncated Library

Dozens of Options to Customise

A standard PepSetTM Peptide Library can be supplied as with a precise length and offset designed to best suit your assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence. Arrange a consultation to discuss your options and design your library.

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Mapping the RNA therapeutics R&D landscape in 2022 Go to article: In this issueGo to article: ContentsGo to article: CSafe GlobalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: HOF SonderanlagenbauGo to article: BEA TechnologiesGo to article: CommentGo to article: Restrictive Medicare coverage spells continued uncertainty for AduhelmGo to article: 2021: a record year for orphan therapiesGo to article: Trikafta/Kaftrio continues to be a game-changer for cystic fibrosis patientsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: In DepthGo to article: Mapping the RNA therapeutics R&D landscape in 2022Go to article: A cloudy day in paradise for pharma tax havens in Cayman Islands & Bermuda?Go to article: Pharmaceutical Technology Excellence Awards 2021 – Winners Announced!Go to article: How technology could transform drug research in 2022Go to article: Anaesthesia drugs worst-hit by US drug shortagesGo to article: Molnar-Institute Company Insight Go to article: Molnar-InstituteGo to article: In DataGo to article: Asia-Pacific sees the largest growth in metabolic disorders-related trials over Go to article: The Middle East has seen the largest growth in infectious disease-related trials over the past decadeGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: BaxterGo to article: EventsGo to article: Next issue